NZ631131A - Reconstituted hdl formulation - Google Patents
Reconstituted hdl formulationInfo
- Publication number
- NZ631131A NZ631131A NZ631131A NZ63113113A NZ631131A NZ 631131 A NZ631131 A NZ 631131A NZ 631131 A NZ631131 A NZ 631131A NZ 63113113 A NZ63113113 A NZ 63113113A NZ 631131 A NZ631131 A NZ 631131A
- Authority
- NZ
- New Zealand
- Prior art keywords
- formulation
- reconstituted hdl
- apolipoprotein
- lipid
- mol
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/775—Apolipopeptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Marine Sciences & Fisheries (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Nutrition Science (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261721771P | 2012-11-02 | 2012-11-02 | |
| EP13153903 | 2013-02-04 | ||
| US13/803,863 US9125943B2 (en) | 2012-11-02 | 2013-03-14 | Reconstituted HDL formulation |
| AU2013205684A AU2013205684B2 (en) | 2012-11-02 | 2013-04-10 | Reconstituted hdl formulation |
| PCT/AU2013/001260 WO2014066943A1 (en) | 2012-11-02 | 2013-10-31 | Reconstituted hdl formulation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ631131A true NZ631131A (en) | 2015-12-24 |
Family
ID=47665977
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ631131A NZ631131A (en) | 2012-11-02 | 2013-10-31 | Reconstituted hdl formulation |
Country Status (15)
| Country | Link |
|---|---|
| US (6) | US9125943B2 (enExample) |
| EP (2) | EP2916857B1 (enExample) |
| JP (1) | JP6340372B2 (enExample) |
| KR (1) | KR102263810B1 (enExample) |
| CN (2) | CN104755096B (enExample) |
| AU (1) | AU2013205684B2 (enExample) |
| BR (1) | BR112015009748B1 (enExample) |
| CA (1) | CA2889785C (enExample) |
| IL (1) | IL238504B (enExample) |
| MX (1) | MX364587B (enExample) |
| NZ (1) | NZ631131A (enExample) |
| PL (1) | PL2916857T3 (enExample) |
| RU (1) | RU2669568C2 (enExample) |
| SG (1) | SG11201503083UA (enExample) |
| WO (1) | WO2014066943A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3178481T3 (en) | 2010-06-30 | 2019-04-08 | Csl Ltd | FORMULATION WITH RECONSTITUTED HIGH DENSITY LIPOPROTEIN AND PROCEDURE FOR PREPARING THEREOF |
| US9125943B2 (en) * | 2012-11-02 | 2015-09-08 | Csl Limited | Reconstituted HDL formulation |
| DK3004160T3 (da) | 2013-06-05 | 2023-01-23 | Csl Ltd | Fremgangsmåde til fremstilling af apolipoprotein a-i (apo a-i) |
| AU2014305646C1 (en) | 2013-08-08 | 2019-01-17 | Csl Limited | Contaminant removal method |
| WO2018019911A1 (en) | 2016-07-27 | 2018-02-01 | Hartis-Pharma Sarl | Therapeutic combinations to treat red blood cell disorders |
| IL266428B2 (en) * | 2016-11-10 | 2024-12-01 | Csl Ltd | High-density lipoprotein (HDL) is restored to treat myocardial infarction |
| CN112546201A (zh) * | 2019-09-26 | 2021-03-26 | 中国科学院生物物理研究所 | 人工脂蛋白颗粒apoA-Ⅳ脂肪体在治疗和/或预防糖尿病中的应用 |
| WO2025185021A1 (zh) * | 2024-03-05 | 2025-09-12 | 维康平生(北京)生物科技有限公司 | 一种脂肪体的冷冻干燥方法 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1335077C (en) * | 1988-02-08 | 1995-04-04 | Henri Isliker | Process for the manufacture of apolipoproteins from human blood plasma or serum |
| US5652339A (en) | 1993-12-31 | 1997-07-29 | Rotkreuzstiftung Zentrallaboratorium | Method of producing reconstituted lipoproteins |
| MXPA04002848A (es) | 2001-09-28 | 2005-06-06 | Esperion Therapeutics Inc | Prevencion y tratamiento de restenosis por administracion local de medicamento. |
| US20040067873A1 (en) | 2002-05-17 | 2004-04-08 | Dasseux Jean-Louis H. | Method of treating dyslipidemic disorders |
| NZ537006A (en) | 2002-05-17 | 2008-01-31 | Esperion Therapeutics Inc | The use of apolipoprotein A-I Milano, for the manufacture ofa composition for treating preventing or reducing ischemic reperfusion injury in a tissue or organ |
| PE20050438A1 (es) | 2003-10-20 | 2005-06-14 | Esperion Therapeutics Inc | Formulas farmaceuticas, metodos y regimenes de dosificacion para el tratamiento y la prevencion de sindromes coronarios agudos |
| US20070254832A1 (en) * | 2006-02-17 | 2007-11-01 | Pressler Milton L | Methods for the treatment of macular degeneration and related eye conditions |
| KR100992488B1 (ko) | 2006-12-29 | 2010-11-05 | 주식회사 녹십자 | ＡｐｏＡ-Ｉ의 정제방법 및 정제된ＡｐｏＡ-Ｉ을 이용한재구축 ＨＤＬ의 생산 방법 |
| WO2009025754A2 (en) | 2007-08-17 | 2009-02-26 | Csl Behring Gmbh | Methods for purification of alpha-1-antitrypsin and apolipoprotein a-i |
| WO2010057203A2 (en) | 2008-11-17 | 2010-05-20 | The Board Of Regents Of The University Of Texas System | Hdl particles for delivery of nucleic acids |
| DK3178481T3 (en) * | 2010-06-30 | 2019-04-08 | Csl Ltd | FORMULATION WITH RECONSTITUTED HIGH DENSITY LIPOPROTEIN AND PROCEDURE FOR PREPARING THEREOF |
| PT2673296T (pt) * | 2011-02-07 | 2019-01-31 | Cerenis Therapeutics Holding Sa | Complexos de lipoproteínas e sua fabricação e utilização |
| US9125943B2 (en) | 2012-11-02 | 2015-09-08 | Csl Limited | Reconstituted HDL formulation |
-
2013
- 2013-03-14 US US13/803,863 patent/US9125943B2/en active Active
- 2013-04-10 AU AU2013205684A patent/AU2013205684B2/en active Active
- 2013-10-31 SG SG11201503083UA patent/SG11201503083UA/en unknown
- 2013-10-31 JP JP2015539998A patent/JP6340372B2/ja active Active
- 2013-10-31 WO PCT/AU2013/001260 patent/WO2014066943A1/en not_active Ceased
- 2013-10-31 EP EP13851610.9A patent/EP2916857B1/en active Active
- 2013-10-31 NZ NZ631131A patent/NZ631131A/en unknown
- 2013-10-31 EP EP19151328.2A patent/EP3502131A1/en active Pending
- 2013-10-31 CA CA2889785A patent/CA2889785C/en active Active
- 2013-10-31 CN CN201380057007.0A patent/CN104755096B/zh active Active
- 2013-10-31 PL PL13851610T patent/PL2916857T3/pl unknown
- 2013-10-31 CN CN201711141045.0A patent/CN108057023B/zh active Active
- 2013-10-31 KR KR1020157014530A patent/KR102263810B1/ko active Active
- 2013-10-31 RU RU2015120808A patent/RU2669568C2/ru active
- 2013-10-31 BR BR112015009748-0A patent/BR112015009748B1/pt active IP Right Grant
- 2013-10-31 US US14/439,094 patent/US9925236B2/en active Active
- 2013-10-31 MX MX2015004546A patent/MX364587B/es active IP Right Grant
-
2015
- 2015-04-28 IL IL238504A patent/IL238504B/en active IP Right Grant
-
2018
- 2018-02-12 US US15/894,397 patent/US10603355B2/en active Active
-
2020
- 2020-03-23 US US16/826,585 patent/US11464828B2/en active Active
-
2022
- 2022-09-02 US US17/902,580 patent/US11957731B2/en active Active
-
2024
- 2024-04-12 US US18/634,576 patent/US20250099537A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12017501501A1 (en) | Compositions and methods for inhibiting expression of tmprss6 gene | |
| MX337437B (es) | Composiciones topicas para conservador o restaurar la integridad de la mucosa. | |
| EP3378486A3 (en) | Stabilized antibody-containing liquid formulations | |
| EP4438625A3 (en) | Formulation for anti-alpha4beta7 antibody | |
| MX2011013722A (es) | Formulaciones liofilizadas para inmunofarmaceuticos modulares pequeños. | |
| PH12014501628A1 (en) | Stabilized formulations containing anti-ang2 antibodies | |
| MX2010004389A (es) | Formulaciones de vancomicina liposomales. | |
| BR112015012547A2 (pt) | composições de prostaciclina e métodos de sua utilização | |
| WO2014004861A3 (en) | Methods of treating pediatric metabolic syndrome | |
| CL2011003003A1 (es) | Composicion tensioactiva reconstituida que comprende un polipeptido análogo a la proteína surfactante c nativa, un polipeptido análogo a la proteína surfactante b nativa, un fosfolipido monoinsaturado y un fosfolipido saturado, útil para el tratamiento del síndrome de dificultad respiratoria. | |
| IN2014KN01713A (enExample) | ||
| IN2014KN01714A (enExample) | ||
| WO2014076569A3 (en) | Controlled release topical testosterone formulations and methods | |
| BR112014009376A2 (pt) | composições | |
| TN2012000511A1 (en) | Compositions and methods of use for therapeutic low density lipoprotein -related protein 6 (lrp6) antibodies | |
| EA201490760A1 (ru) | R(+)-n-метилпропаргиламиноиндан | |
| MX2012014928A (es) | Una formulacion de lipoproteina de alta densidad reconstituida y metodo de produccion de la misma. | |
| NZ708821A (en) | Lfa-1 inhibitor formulations | |
| MX364587B (es) | Formulaciones reconstituidas de hdl. | |
| MX370211B (es) | Eteres de bis (hidroximetil) ciclohexanos. | |
| CL2009001156A1 (es) | Acetato de un peptido de 12 aminoacidos; metodo de preparacion; composicion farmaceutica y agente que lo contiene, solo o conjuntamente con un principio activo que dana el acido nucleico; util para el tratamiento o profilaxis de trastornos proliferativos celulares. | |
| MX2012007682A (es) | Vacuna de aplicacion nasal contra el desarrollo de la enfermedad aterosclerotica y el higado graso. | |
| MX2016005720A (es) | Composiciones y metodos para administracion de una enzima a las vias respiratorias de un sujeto. | |
| WO2013048599A3 (en) | Ketol-acid reductoisomerases with improved performance properties | |
| MY168692A (en) | The treatment of viral infections |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 31 OCT 2018 BY CPA GLOBAL Effective date: 20170914 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 31 OCT 2019 BY CPA GLOBAL Effective date: 20180913 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 31 OCT 2020 BY CPA GLOBAL Effective date: 20190919 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 31 OCT 2021 BY CPA GLOBAL Effective date: 20200917 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 31 OCT 2022 BY CPA GLOBAL Effective date: 20210916 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 31 OCT 2023 BY CPA GLOBAL Effective date: 20220915 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 31 OCT 2024 BY CPA GLOBAL Effective date: 20230914 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 31 OCT 2025 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS Effective date: 20240919 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 31 OCT 2026 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS Effective date: 20250918 |